Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by BioLife Solutions in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: BioLife Solutions’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:22 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054355
| (In thousands, except per share and share data) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| General and administrative | 10,694 | 11,232 | 22,901 | 22,582 |
| Sales and marketing | 2,782 | 2,577 | 5,308 | 5,020 |
| Research and development | 2,958 | 1,965 | 5,608 | 3,404 |
| IPR&D expense | — | 15,521 | — | 15,521 |
| Intangible asset amortization | 157 | 66 | 242 | 132 |
| Total operating expenses | 16,591 | 31,361 | 34,059 | 46,659 |
| Operating income (loss) | 1,696 | (16,126) | 1,725 | (16,624) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is BioLife Solutions's R&D?
- BioLife Solutions (BLFS) reported R&D of $2.96M in Q2 2026.
- How has BioLife Solutions's R&D changed year-over-year?
- BioLife Solutions's R&D increased by 50.5% year-over-year, from $1.97M to $2.96M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about BioLife Solutions's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude